Drugs / Cell culture derived influenza vaccine
Cell culture derived influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00630331 | Oct 2007 → Jul 2008 | influenza | Novartis Vaccines | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00306527 Comparator | Sep → Dec 2005 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell culture-derived influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630331 ↗ |
| Known as | CCIV | “cell culture-derived (CCIV; Optaflu(®))” PMID 22418809 ↗ May 2012 |
| Known as | cTIV | “cell-derived trivalent influenza vaccine (cTIV)” NCT00306527 ↗ |
| Known as | Optaflu | “METHODS: A total of 11,404 study participants aged 18-49 years were randomized equally to receive CCIV (Optaflu; n = 3828), TIV (Agrippal; n = 3676), or placebo (n = 3900).” PMID 20868284 ↗ Nov 20101“cell culture-derived (CCIV; Optaflu(®))” PMID 22418809 ↗ May 2012 |
| Modality | Vaccine | “Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.” PMID 20868284 ↗ Nov 2010 |
| Route | Intramuscular | “as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm” NCT00306527 ↗ |